Teva acquires movement disorder-focused Auspex for $3.2bn
True to its words in late 2014 that it would be refocusing efforts toward neurological disease, Teva Pharmaceutical Industries Ltd. bought publicly traded Auspex Pharmaceuticals Inc. (rare diseases, specifically movement disorders) for $3.2bn ($101 per share, a 32% premium).
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.